COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04614948 Janssen Pharmaceutical Companies Hardt K, Lancet Infect Dis, 2022 a ENSEMBLE2 Full text Full text Commentary |
Non replicating viral vector |
Ad26.COV2.S 5x10^10vp D0 |
Placebo |
RCTPhase 3 | Adults, healthy or with stable and well-controlled comorbidities, at 125 centers in Belgium, Brazil, Colombia, France, Germany, The Philippines, South Africa, Spain, UK, and USA | N= 31,835 |
Some concerns Details |
|
|
NCT04436276 Janssen Pharmaceutical Companies Sadoff J, N Engl J Med, 2021 a ENSEMBLE Full text Commentary |
Non replicating viral vector |
Ad26.COV2.S, 5x10^10vp |
0.9% saline placebo |
RCTPhase 1-2 | Healthy SARS-CoV-2 nucleic acid negative adults 18-55 years old and elderly >65 years old in multiple centres in Belgium and the US | N= 810 |
Low Details |
|
|
NCT04505722 Janssen Pharmaceutical Companies Sadoff J, N Engl J Med, 2022 b ENSEMBLE Full text Full text Commentary |
Non replicating viral vector |
Ad26.COV2.S 5x10^10vp |
Placebo |
RCTPhase 3 | Adults >18 years of age at 213 centers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and USA | N= 44325 |
Some concerns Details |
|